Background Both infarct size and microvascular obstruction (MO) assessed by cardiac magnetic resonance imaging (CMR) are known to be predictors for adverse clinical outcome after ST-elevation myocardial infarction (STEMI). We hypothesized that a ratio of MO and infarct size (MO/infarct size) might be an even stronger predictor for outcome after STEMI, which has not been investigated yet. Methods STEMI patients reperfused by primary angioplasty (n = 438) within 12 h after symptom onset underwent contrast-enhanced CMR at a median of 3 days (interquartile range [IQR] 2;4) after the index event. MO and infarct size were measured 15 min after intravenous gadolinium injection. Follow-up was conducted after 19 months (IQR 10;27). The primary end point was defined as a composite of death, non-fatal myocardial reinfarction and congestive heart failure (major adverse cardiac events [MACE]). Results The extent of MO was only weakly correlated with infarct size (r = 0.21, p \ 0.001). In a first multivariate analysis including extent of MO, infarct size, ejection fraction, end-systolic and end-diastolic volume, the extent of MO was independently associated with MACE (hazard ratio [HR] 1.03, 95%CI 1.02-1.05, p \ 0.001). In a second multivariate analysis including MO/infarct size on top of the extent of MO, infarct size, ejection fraction, end-systolic and end-diastolic volume, MO/infarct size was identified as the strongest independent predictor for MACE (HR 2.22 [95%CI 1.60-3.08, p \ 0.001]).
Introduction
In acute ST-elevation myocardial infarction (STEMI), reperfusion has contributed to improved survival due to limitation of myocardial necrosis. In daily clinical practice, assessment of reperfusion success is performed using surrogate markers including clinical, angiographic and electrocardiographic parameters [1] [2] [3] [4] . In contrast to indirect markers of myocardial ischemia such as troponin [5] [6] [7] , with the introduction of cardiac magnetic resonance imaging (CMR), direct visualization and quantification of infarct expansion and microvascular obstruction (MO) have been made possible [8] [9] [10] . Both infarct size and MO have been shown to be prognostic markers for adverse clinical outcome after STEMI [11] [12] [13] [14] . We could previously demonstrate that MO is a strong independent prognostic marker for hard clinical end points, even after adjustment for traditional outcome measures [15] . However, we observed that some patients displayed large zones of infarcted myocardium constituting of only small areas of MO, whereas others displayed infarcts mainly constituting of MO. MO reflects zones of impaired microcirculation and its development is influenced by factors beyond the actual ischemic damage of the myocyte, such as reperfusion injury, swelling and protrusion of the endothelial cells, leading to compression of the capillaries, microvascular plugging by neutrophils, red blood cells and platelets and even rupture of the microvessels [16] . In contrast, the infarcted non-obstructed regions display intact or less impaired microvasculature and it is therefore likely that this leads to differing pathophysiological consequences [17] . Thus, we hypothesized that a ratio of MO and infarct size (MO/infarct size) might be a better predictor for clinical outcome than either parameter on its own, which has not been investigated so far. Furthermore, previous studies analyzing the relation of infarct size and MO led to inconsistent results and are limited due to small study cohorts, analysis of combined end points including weak components (including unstable angina, re-hospitalization and repeat revascularization) and relatively short follow-up periods [11, 14, 18] .
We therefore sought to analyze the comparative impact and relation of (1) MO, (2) infarct size and (3) MO/infarct size as predictors for long-term clinical outcome after STEMI in a large prospective cohort.
Methods

Patients and study design
From February 2006 to July 2008, 512 consecutive STEMI patients underwent primary percutaneous coronary intervention (PCI). Inclusion criteria were the presence of symptoms \12 h and ST-segment elevation in C2 leads with C0.2 mV in the precordial leads or C0.1 mV in extremity leads. Data from the current cohort were previously analyzed to study the impact of early versus late MO on clinical outcome after STEMI [15] . Patients with prior fibrinolysis and contraindications to CMR at study entry were excluded. All patients received 500 mg of aspirin and unfractionated heparin (60 IU/kg bodyweight) intravenously prior to PCI. Clopidogrel with a 600-mg loading dose and subsequently 75 mg for 12 months plus aspirin indefinitely were mandatory. All other medications including glycoprotein IIb/IIIa-inhibitors were administered according to current guidelines [19, 20] .
Primary PCI was performed according to standard clinical practice. Additional thrombectomy was used depending on thrombus burden in the infarct-related artery. Coronary angiography of the target lesion, defined as an angiographically significant stenosis with significant ST-elevations in the corresponding ECG-leads, was performed before and after PCI with the same projections to allow optimal offline evaluation of the thrombolysis in myocardial infarction (TIMI) flow of the infarct-related artery by two independent observers [2] .
The TIMI-risk score was calculated as described previously [4] . Early ST-segment resolution, expressed as percentage from before to after PCI, was evaluated by measuring the sum of ST-segment elevation 20 ms after the end of the QRS complex in the ECG before and after PCI [3] .
The study was approved by the University of Leipzig Ethics Committee and all patients gave written informed consent.
CMR imaging
All patients were examined at rest in the supine position with a whole-body 1.5-T MR scanner (Gyroscan Intera CV, Philips Medical Systems, Best, The Netherlands) equipped with a five-element cardiac phased-array coil for signal reception. A vectorcardiogram for gating and triggering was used. To define the orientation of the heart, a real-time interactive tool was applied. All images were acquired during breath-hold at end expiration.
Left ventricular (LV) function was assessed by a standard steady-state free precession technique acquiring shortaxis slices from base to apex and also horizontal and vertical long-axis views. Delayed enhancement short-axis images covering the whole ventricle were acquired at mid-diastole approximately 15 min after bolus injection (0.2 mmol/kg/ bodyweight) of gadolinium-chelate (Gadovist, Schering, Germany). A three-dimensional inversion-recovery (IR) turbo gradient echo sequence (typical spatial resolution 2.0 9 2.0 9 5 mm, prepulse delay 175-300 ms) was used for image acquisition. The individual IR prepulse delay was defined to obtain the maximal contrast between viable and necrotic myocardium. Additionally, myocardial edema imaging was performed to differentiate between acute and chronic infarction, acquiring three short-axis slices using a T2-weighted turbo spin-echo sequence before contrast administration. Only delayed enhancement displaying the typical pattern of myocardial infarction with corresponding myocardial edema was interpreted as the CMR equivalent for the acute event and thus was further analyzed [21] .
CMR measurements were performed off-line in a CMR core laboratory by observers blinded to clinical, angiographic and electrocardiographic parameters. The performance of the CMR core laboratory has been demonstrated previously [22, 23] . LV ejection fraction (EF), end-diastolic and end-systolic volumes were calculated from the shortaxes functional views. LV function was graded according to the corresponding EF: \25, 25-35, 35-45, 45-55 and [55%. LV mass was assessed for the delayed enhancement images by tracing the endocardial and epicardial contours manually; papillary muscles were included. Once the myocardial contours were identified, the infarct size was determined by manual delineation of delayed enhancement in each of the short-axis images. MO was assessed 1 and 15 min after gadolinium injection (early and persistent MO). The current analysis was limited to persistent MO due to its superior prognostic value in comparison to early MO [13, 24, 25] . The obstructed area within the infarction of the short-axes slices was manually drawn. MO was analyzed qualitatively (=presence of MO) and quantitatively (=extent of MO expressed as percentage of LV mass [%LV]). Infarct size was expressed as %LV. The MO/infarct size ratio was calculated for all patients.
End points and definitions
Clinical follow-up was conducted via a structured questionnaire by telephone. Any clinical event was verified by hospital charts, or direct contact with the treating physician or contact with the local government registration. The follow-up interviewer was not aware of the results of the CMR studies.
The primary end point was defined as major adverse cardiac events (MACE) comprising a composite of death, non-fatal myocardial reinfarction and congestive heart failure. Death was defined as death from any cause; however, it was further classified as cardiac and non-cardiac death. Death was regarded as cardiac in origin unless obvious non-cardiac causes could be identified. In case of any doubt, death was counted as cardiac. The diagnosis of reinfarction during the index hospitalization was based on clinical symptoms, new ST-segment changes and an increase in the creatine kinase-MB levels above the reference limits in patients with normalized values or if there was an increase of C20% from the last non-normalized measurement [26] . At follow-up, any new ischemic symptoms requiring hospital admission accompanied by troponin elevation were defined as recurrent myocardial infarction [26] . New heart failure was defined as any congestive heart failure (rales, dyspnea, New York Heart Association class III-IV) leading to medical attention [24 h after the index event. In patients experiencing[1 event, the first event was chosen for the combined clinical end point. When C1 events occurred simultaneously, the most severe event was chosen (death [ myocardial reinfarction [ congestive heart failure). All outcomes were adjudicated by a clinical events committee unaware of the CMR results.
Statistical analysis
Each categorical variable is expressed as the number and percentage of patients. Continuous data are reported as medians with the corresponding interquartile range (IQR).
For comparison of continuous data, the nonparametric Wilcoxon rank-sum test was used. Survival curves were estimated using Kaplan-Meier distributions with log-rank comparison to illustrate the time-dependent occurrence of the combined clinical end point in relation to the presence of MO, as well as to infarct size and MO/infarct size for Cmedian versus \median.
We fitted univariate Cox proportional-hazards models to estimate the hazard ratios (HR) for the combined clinical end point. All parameters with a p value \0.05 entered multivariate analysis, which was performed using a stepwise algorithm. A first multivariate Cox regression analysis was performed including extent of MO, infarct size, EF, endsystolic and end-diastolic volume. A second multivariate Cox regression analysis was fitted including MO/infarct size as well as the extent of MO, infarct size, EF, end-systolic and end-diastolic volume. In the subgroup of patients displaying extensive myocardial damage defined as an infarct size Cmedian, a third multivariate analysis including the parameters of the second multivariate model was performed. In univariate and multivariate Cox regression analysis, parameters were included as continuous variables.
All statistical tests were performed with SPSS software, version 17.0 (SPSS Inc., Chicago, Il). All probability values were two tailed with a = 0.05 and all confidence intervals (CI) were calculated to the 95th percentile.
Results
Of the 512 STEMI patients referred for primary PCI, 438 underwent CMR 2-7 days (in median 3 days [IQR 2;4]) after the index event with a similar time delay between patients with and without MO (p = 0.65). In addition, infarct size did not differ significantly according to the time of CMR image acquisition (p = 0.73). In total, 74 patients had to be excluded from CMR due to claustrophobia (n = 19), death before CMR (n = 18), refusal (n = 15), prior pacemaker implantation (n = 5), obesity (n = 7), metallic implant (n = 1), dyspnea (n = 2) or technical reasons (n = 7). Patient follow-up was performed at a median of 19 months (IQR 11;27) after index infarction and was completed for 97% of the patients (n = 423).
All patients displayed myocardial edema in the infarct region indicative of acute myocardial infarction. In addition, 10% of all patients (n = 42) displayed delayed enhancement with a typical post-infarction pattern, but without corresponding edema in T2-weighted imaging. These regions were interpreted as chronic or prior myocardial infarctions and were therefore not further analyzed. The median infarct size in the overall study cohort was 17.7%LV (IQR 8.5;28.0) and MO was detected in 68% (n = 296) of patients involving 1.2%LV (IQR 0.6;3.0). Infarct size and MO were only weakly correlated (r = 0.21). The median value of MO/infarct size was 0.07 (IQR 0.03;0.13) ranging from 0 to 1. A typical patient example showing infarct size and the corresponding MO is shown in Fig. 1 .
Baseline clinical characteristics as well as electrocardiographic, angiographic and CMR data are shown in Table 1 . Importantly, 89.7% of all patients (n = 379) received glycoprotein IIb/IIIa-inhibitors. However, we could not observe an association between administration of glycoprotein IIb/IIIa-inhibitors and MO (presence of MO: p = 0.38/extent of MO: p = 0.22).
Outcome analysis
Overall, 69 events were recorded throughout the follow-up period consisting of death in 25 patients (cardiac death n = 20, stroke n = 4, cancer n = 1), non-fatal myocardial infarctions in 19 
Prognostic evaluation
Kaplan-Meier curves revealed a significant association of MO, infarct size and MO/infarct size with the occurrence of MACE ( Fig. 2a-d ). In comparison to the extent of MO, infarct size, EF, and end-systolic and end-diastolic volume, MO/infarct size demonstrated the strongest unadjusted association with MACE ( Table 2) .
In a first multivariate analysis including extent of MO, infarct size, EF as well as end-systolic and end-diastolic volume, the extent of MO remained independently associated with MACE (HR 1.03, 95%CI 1.02-1.05, p \ 0.001; Table 3 ).
In a second multivariate analysis including MO/infarct size on top of the parameters included in the first model, MO/ infarct size was identified as the strongest independent predictor for MACE (HR 2.22; 95%CI 1.60-3.08, p \ 0.001; Table 4 ).
In the subgroup of patients displaying extensive myocardial damage defined as an infarct size Cmedian, a third multivariate analysis including the parameters of the second multivariate model, MO/infarct size was the only independent predictor for MACE (HR 2.03; 95%CI 1.38-2.98, p \ 0.001).
Discussion
The main findings of this large outcome analysis in STEMI patients using CMR parameters can be summarized as follows: (1) presence and extent of MO, infarct size and MO/infarct size were associated with adverse clinical outcome defined by death, reinfarction and congestive heart failure in univariate analysis; (2) in contrast to infarct size, the extent of MO was independently associated with MACE; (3) the newly introduced MO/infarct size ratio is an even stronger predictor for long-term prognosis after STEMI than either parameter alone.
With the introduction of CMR, it has been made possible to directly visualize and quantify regions of acute myocardial infarction and identify zones of impaired microperfusion, also referred to as MO. In animal models, an almost exact relationship between the extent and shape of MO and infarct size assessed by CMR and histopathological results could be demonstrated [9, 27] . The results of previous trials examining MO and infarct size as outcome measures have been ambiguous: Wu et al. [11] reported a significant association of infarct size with worse clinical outcome independent of other CMR parameters, such as MO. In contrast, in other studies, infarct size did not remain significant in multivariate analysis adjusting for traditional CMR parameters [12, 13] . Our results could confirm these findings, which are supported by previous studies identifying MO as a stronger predictor for LV remodeling in the post-infarction period than infarct size [24, 28] . This might be explained in part by altered local properties in the presence of MO, as well as pre-existing patient characteristics influencing both the development of MO and post-infarction outcome, such as endothelial dysfunction [16, 29] .
Since infarct size and MO have both been associated with adverse clinical outcome after STEMI, we hypothesized that the analysis of a ratio of the two parameters might add incremental prognostic value, as the extent of MO can widely differ in infarctions of similar size as demonstrated in Fig. 1 . Indeed, we could demonstrate a strong prognostic association of MO/infarct size with longterm clinical outcome after STEMI. The pathophysiological consequences and the consecutive impact on functional recovery after STEMI of an expansion of MO and infarct size might be slightly different. While MO reflects truly non-viable regions associated with greater apoptosis and cellular loss leading to local involution and wall thinning [30] , infarct expansion might also increase wall stress in adjacent or remote non-infarcted regions [31] . The extent of infarct size and the development of MO are influenced by diverging parameters, as MO is known to be associated with factors beyond the ischemic damage itself, such as reperfusion injury. Our data emphasize, therefore, the Maximal creatine kinase, lmol/l 6. importance of reperfusion strategies aiming at a reduction of infarct size while preserving microvascular function, such as thrombectomy. Therefore, it is conceivable that MO/infarct size represents a broader reflection of the degree of injury after STEMI than the separate analysis and may therefore be considered as an outcome measure for future reperfusion studies. Focusing solely on infarct size independent of the microvascular state might not improve the clinical outcome in patients. As CMR visualizes and quantifies both infarct size and MO accurately, it may be judged as a principal imaging technique in studies evaluating reperfusion success in the setting of STEMI.
Some limitations of the current trial need to be addressed. First, we performed CMR in median 3 days (IQR 2;4) after the index event. Despite previously published data on animals indicating a stable phase of infarct size and MO between day 2 and 7 after the acute ischemic event [32] , there is emerging evidence that infarct size assessed by CMR decreases within the first week after STEMI [33] [34] [35] [36] . However, these data are limited due to small study sample sizes and a selection in patients. In addition, the exact evolvement of post-infarction CMR parameters within the first few days after the index event has not been investigated in a large cohort of unselected STEMI patients so far. Fig. 2 a Major adverse cardiovascular events with and without microvascular obstruction. Kaplan-Meier curve for the cumulative incidence of major adverse cardiac events in patients with and without microvascular obstruction (MO). b Major adverse cardiovascular events depending on median infarct size. Kaplan-Meier curve for the cumulative incidence of major adverse cardiac events in patients with an infarct size \median versus Cmedian. c Major adverse cardiovascular events depending on median ratio of microvascular obstruction/infarct size. Kaplan-Meier curve for the cumulative incidence of major adverse cardiac events in patients with a ratio of microvascular obstruction and infarct size (MO/infarct size) \median versus Cmedian. d Major adverse cardiovascular events depending on the presence of microvascular obstruction and the median ratio of microvascular obstruction/infarct size. Kaplan-Meier curve for the cumulative incidence of major adverse cardiac events in patients without microvascular obstruction (MO) versus with MO, and a ratio of MO and infarct size (MO/infarct size) \median versus with MO and a MO/infarct size Cmedian
In the current study, CMR image acquisition was performed in a relatively narrow period of time in comparison to many previously published studies (in median 3 days after STEMI, IQR 2;4). However, we cannot definitely rule out potential changes of infarct size and MO within the first days after myocardial ischemia, although it is unlikely that these changes would substantially influence the current results. Indeed, neither infarct size nor MO was significantly influenced by the timing of CMR assessment following infarction. Second, CMR image analysis was performed by manual delineation. Recently, an alternative method using automatic planimetry for quantification of infarct size and MO has been suggested to achieve higher reproducibility. However, the optimal method for automatic analysis has not been fully established [37] [38] [39] and notably our CMR core laboratory has proven excellent reproducibility and low interobserver and intraobserver variability for manual analysis of infarct size [22, 23] . Given these issues, we prefer to planimeter the infarct manually in our core laboratory using experienced readers who can carefully segment myocardial borders and can account for artifacts, no-reflow regions and areas with intermediate image intensity. Third, the study sample size is still limited to draw definitive conclusions on clinical outcome. Finally, all patients were treated at a single high-volume tertiary referral center. As a consequence, the results may not be generalized to the entire STEMI population.
In conclusion, in contrast to infarct size, the extent of MO is associated with adverse clinical outcome after STEMI even after adjustment for other CMR parameters. However, MO/infarct size is an even more powerful predictor for long-term outcome after STEMI.
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